| scholarly article | Q13442814 |
| P356 | DOI | 10.3760/CMA.J.ISSN.0253-2727.2015.11.019 |
| P698 | PubMed publication ID | 26632476 |
| P2093 | author name string | Wei Xu | |
| Jianyong Li | |||
| Huayuan Zhu | |||
| P2860 | cites work | Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial | Q28286064 |
| Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma | Q33380352 | ||
| Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia | Q33385646 | ||
| Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study | Q33396465 | ||
| Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group | Q33396737 | ||
| Bendamustine plus mitoxantrone for relapsed/refractory chronic lymphocytic leukaemia (CLL): results of a multicentre phase II study of the German CLL Study Group (GCLLSG). | Q33401132 | ||
| Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group | Q33402713 | ||
| Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia | Q33405428 | ||
| Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation | Q33405812 | ||
| The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia | Q33406164 | ||
| Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma | Q33407529 | ||
| Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma | Q33409872 | ||
| A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma | Q33418456 | ||
| Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study | Q34663603 | ||
| The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma | Q34707136 | ||
| Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial | Q35560022 | ||
| The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. | Q35583403 | ||
| Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin's lymphoma | Q38417140 | ||
| The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia | Q39180275 | ||
| A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study | Q41418657 | ||
| Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial. | Q42627572 | ||
| Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. | Q53171451 | ||
| Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial. | Q55056539 | ||
| Bendamustine therapy in patients with relapsed or refractory Waldenström's macroglobulinemia | Q83757867 | ||
| Bendamustine as salvage treatment for patients with relapsed or refractory mantle cell lymphoma patients: a retrospective study of the Spanish experience | Q87783023 | ||
| P433 | issue | 11 | |
| P921 | main subject | bendamustine | Q425745 |
| non-Hodgkin lymphoma | Q1138590 | ||
| P304 | page(s) | 972-976 | |
| P577 | publication date | 2015-11-01 | |
| P1433 | published in | Chinese Journal of Hematology | Q27714364 |
| P1476 | title | [Progress of bendamustine in the treatment of B cell non-Hodgkin lymphoma] | |
| P478 | volume | 36 |
Search more.